Intelisci reposted this
BridgeBio has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, which is backed by $300 million in funding from investors that include Viking Global Investors and Sequoia Capital. The new company will inherit drug programs aimed at the rare diseases erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex. https://lnkd.in/eJDbhanB #startups #startup #spinout #raredisease #orphandrug #pharma #business #businessintelligence #lifesciences
